SIL204 treatment may help immune system attack KRAS-driven tumors, research finds – exclusive

by NOWlej | Aug 5, 2026 | JPost | 0 comments

Illustration of a pancreatic tumor surrounded by immune cells (photo credit: Silexion spokesperson)
This comes just after SIL204 advanced into Phase 2/3 clinical evaluation at the end of July, beginning its first clinical trial at Tel Aviv Sourasky Medical Center.

Subscribe to JPost Premium

Recent Posts

The rise and fall of StreamElements
Aug 5, 2026 5:10 pm | Globes Tech
After firing 600 workers monday.com CEOs seek double pay
Aug 5, 2026 4:57 pm | Business, JPost Biztech
Study: How donors can improve humanitarian aid for women
Aug 5, 2026 4:25 pm | Business, JPost Biztech
Michael J Sacks on the connection between business growth and community investment
Aug 5, 2026 4:09 pm | Business, JPost Biztech
Israeli cyber startup Oligo Security doubles valuation with $60 Million round
Aug 5, 2026 4:00 pm | Innovation, JPost Tech